Cerus Corp (NASDAQ: CERS)

Cerus Corp, known by its ticker symbol CERS, operates in the biomedical products industry with a focus on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company's primary business activities involve creating and marketing products that inactivate blood-borne pathogens in donated blood components intended for transfusion.

Cerus Corp's INTERCEPT Blood System is designed to decrease blood-borne pathogens in platelets, plasma, and red blood cells, which are utilized in transfusions. This system employs a unique technology that uses a small molecule compound, amotosalen, to form bonds with nucleic acid in pathogens, thereby inactivating them. The system has received regulatory approvals in several countries, such as the United States, European Union, and others.

The company's revenue is generated primarily through the sale of its products, including the INTERCEPT Blood System for platelets, plasma, and cryoprecipitation. These products are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion. Cerus Corp sells its products directly to blood centers and hospitals, and also collaborates with distributors to expand its reach.

Cerus Corp holds a strong position within the blood safety market, thanks to its proprietary technology that has received regulatory approvals in several countries. The company's main competitors include those offering alternative pathogen reduction technologies for platelets and plasma, as well as those developing and selling diagnostic screening products to detect and prevent contaminated products from being transfused. The company believes that its INTERCEPT Blood System has certain competitive advantages over other blood-borne pathogen reduction methods, particularly its ability to inactivate pathogens in platelets and plasma donated for transfusion.

The company's customers include blood centers, hospitals, and other healthcare organizations. These customers are located in various regions, including the United States, European Union, and others.

The INTERCEPT Blood System includes several products, such as the Platelet System, Plasma System, and Cryoprecipitation System. The Platelet System is designed for ex vivo preparation of pathogen-reduced apheresis platelet components to reduce the risk of transfusion-transmitted infections (TTIs) and as an alternative to gamma irradiation for prevention of transfusion-associated graft versus host disease (TA-GVHD). The Plasma System is designed for ex vivo preparation of pathogen-reduced, whole blood-derived or apheresis plasma to reduce the risk of TTIs when treating patients requiring therapeutic plasma transfusion and as an alternative to gamma irradiation for prevention of TA-GVHD. The Cryoprecipitation System is designed to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency and to produce pathogen-reduced plasma, cryoprecipitate.